RxDoctor Payments Data

Ellen Berkenkemper

Family · Winchester, VANPI 1356858252

Payments from drug & device makers

$3,232in general payments, 2019–2025

Across 131 payments — averaging $24.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$699
  • Nevro Corp.$393
  • Collegium Pharmaceutical, Inc.$357
  • Boston Scientific$273
  • Nalu Medical, Inc.$212
  • Relievant Medsystems, Inc.$212
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,232100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,232 in reported general payments places this provider in the 85th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$166,469
Medicare patients
434
Services billed
1,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl120$100,580
Xtampza ErOxycodone Myristate185$99,457
OxycontinOxycodone Hcl66$35,077
Fentanyl395$29,864
Nucynta ErTapentadol Hcl15$20,349
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen896$16,273
MovantikNaloxegol Oxalate27$14,056
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen716$13,392
Buprenorphine90$12,782
Pregabalin625$11,115
Morphine Sulfate ErMorphine Sulfate390$11,054
Gabapentin507$7,577
Tramadol Hcl700$5,484
Hydrocodone Bitartrate ErHydrocodone Bitartrate11$4,919
Tramadol Hcl ErTramadol Hcl78$4,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta Er$357$220,386320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,332 family providers in Virginia.

Other family in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →